Business Description
Shenzhen Hepalink Pharmaceutical Group Co Ltd
NAICS : 325412
ISIN : CNE100003YN2
Share Class Description:
HKSE:09989: Class HCompare
Compare
Traded in other countries / regions
002399.China09989.Hong KongSHEZF.USA IPO Date
2020-07-08Description
Shenzhen Hepalink Pharmaceutical Group Co Ltd is a China-based company engaged in biopharmaceutical production, biopharmaceutical services, biopharmaceutical trading, and biopharmaceutical research and development. The company distributes its products both in the domestic and overseas markets. The Group mainly operates three main business segments, including the Finished dose pharmaceutical products business; Active pharmaceutical ingredients; CDMO business, and Others. The geographical presence of the company is in Hong Kong, the United States of America, Europe, Mainland China, and Other countries. The majority of the company's revenue comes from USA and Europe.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.58 | |||||
| Equity-to-Asset | 0.65 | |||||
| Debt-to-Equity | 0.38 | |||||
| Debt-to-EBITDA | -32.41 | |||||
| Interest Coverage | 4.43 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | 2.12 | |||||
| Beneish M-Score | -2.81 | |||||
| WACC vs ROIC | ||||||
Growth Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -2 | |||||
| 3-Year FCF Growth Rate | 37.2 | |||||
| 3-Year Book Growth Rate | 1 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 7.96 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 61.42 | |||||
| 9-Day RSI | 51.11 | |||||
| 14-Day RSI | 48.15 | |||||
| 6-1 Month Momentum % | 18.62 | |||||
| 12-1 Month Momentum % | -16.3 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.39 | |||||
| Quick Ratio | 1.05 | |||||
| Cash Ratio | 0.6 | |||||
| Days Inventory | 683.41 | |||||
| Days Sales Outstanding | 81.88 | |||||
| Days Payable | 33.3 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Dividend Growth Rate | -17.8 | |||||
| Shareholder Yield % | 10.28 |
Profitability Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 32.9 | |||||
| Operating Margin % | 14.83 | |||||
| Net Margin % | -4.36 | |||||
| FCF Margin % | 33.1 | |||||
| ROE % | -1.99 | |||||
| ROA % | -1.25 | |||||
| ROIC % | 4.11 | |||||
| 3-Year ROIIC % | -23.58 | |||||
| ROC (Joel Greenblatt) % | -1.45 | |||||
| ROCE % | -0.97 | |||||
| Years of Profitability over Past 10-Year | 9 |
GF Value Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Forward PE Ratio | 6.14 | |||||
| PE Ratio without NRI | 19.76 | |||||
| Shiller PE Ratio | 22.72 | |||||
| PS Ratio | 2.41 | |||||
| PB Ratio | 1.11 | |||||
| Price-to-Tangible-Book | 1.44 | |||||
| Price-to-Free-Cash-Flow | 7.3 | |||||
| Price-to-Operating-Cash-Flow | 6.01 | |||||
| EV-to-EBIT | -98.77 | |||||
| EV-to-EBITDA | -98.77 | |||||
| EV-to-Revenue | 2.51 | |||||
| EV-to-FCF | 7.62 | |||||
| Price-to-Projected-FCF | 1.49 | |||||
| Price-to-Median-PS-Value | 0.41 | |||||
| Price-to-Graham-Number | 1.13 | |||||
| Price-to-Net-Current-Asset-Value | 3.14 | |||||
| Earnings Yield (Greenblatt) % | -1.01 | |||||
| FCF Yield % | 15.23 | |||||
| Forward Rate of Return (Yacktman) % | -21.67 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Shenzhen Hepalink Pharmaceutical Group Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil HK$) | 6,028.47 | ||
| EPS (TTM) (HK$) | -0.189 | ||
| Beta | 0.8 | ||
| Volatility % | 42.91 | ||
| 14-Day RSI | 48.15 | ||
| 14-Day ATR (HK$) | 0.077969 | ||
| 20-Day SMA (HK$) | 3.3395 | ||
| 12-1 Month Momentum % | -16.3 | ||
| 52-Week Range (HK$) | 2.39 - 4.2 | ||
| Shares Outstanding (Mil) | 1,467.3 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Shenzhen Hepalink Pharmaceutical Group Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Shenzhen Hepalink Pharmaceutical Group Co Ltd Stock Events
| Event | Date | Price(HK$) | ||
|---|---|---|---|---|
| No Event Data | ||||
Shenzhen Hepalink Pharmaceutical Group Co Ltd Frequently Asked Questions
What is Shenzhen Hepalink Pharmaceutical Group Co Ltd(HKSE:09989)'s stock price today?
The current price of HKSE:09989 is HK$3.33. The 52 week high of HKSE:09989 is HK$4.20 and 52 week low is HK$2.39.
When is next earnings date of Shenzhen Hepalink Pharmaceutical Group Co Ltd(HKSE:09989)?
The next earnings date of Shenzhen Hepalink Pharmaceutical Group Co Ltd(HKSE:09989) is .
Does Shenzhen Hepalink Pharmaceutical Group Co Ltd(HKSE:09989) pay dividends? If so, how much?
Shenzhen Hepalink Pharmaceutical Group Co Ltd(HKSE:09989) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers